These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 25108211)
1. Ion channels and transporters as therapeutic targets in the pulmonary circulation. Olschewski A; Papp R; Nagaraj C; Olschewski H Pharmacol Ther; 2014 Dec; 144(3):349-68. PubMed ID: 25108211 [TBL] [Abstract][Full Text] [Related]
2. Endothelial and smooth muscle cell ion channels in pulmonary vasoconstriction and vascular remodeling. Makino A; Firth AL; Yuan JX Compr Physiol; 2011 Jul; 1(3):1555-602. PubMed ID: 23733654 [TBL] [Abstract][Full Text] [Related]
3. Special topics issue of microcirculation: ion channels and pulmonary vascular function. Townsley MI Microcirculation; 2006 Dec; 13(8):611-3. PubMed ID: 17085422 [TBL] [Abstract][Full Text] [Related]
4. Ion Channels in Pulmonary Hypertension: A Therapeutic Interest? Lambert M; Capuano V; Olschewski A; Sabourin J; Nagaraj C; Girerd B; Weatherald J; Humbert M; Antigny F Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30322215 [TBL] [Abstract][Full Text] [Related]
5. Modulation of ion channels in pulmonary arterial hypertension. Guibert C; Marthan R; Savineau JP Curr Pharm Des; 2007; 13(24):2443-55. PubMed ID: 17692012 [TBL] [Abstract][Full Text] [Related]
6. [Upregulation/downregulation of ion channels in pulmonary hypertension]. Yamamura A Nihon Yakurigaku Zasshi; 2016; 148(5):226-230. PubMed ID: 27803434 [No Abstract] [Full Text] [Related]
7. Existing drugs and agents under investigation for pulmonary arterial hypertension. Sharma M; Pinnamaneni S; Aronow WS; Jozwik B; Frishman WH Cardiol Rev; 2014; 22(6):297-305. PubMed ID: 25098201 [TBL] [Abstract][Full Text] [Related]
8. [Novel concepts in the pathobiology of pulmonary arterial hypertension]. Rosenkranz S Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S167-9. PubMed ID: 18814087 [TBL] [Abstract][Full Text] [Related]
9. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Dumas de la Roque E; Savineau JP; Bonnet S Pharmacol Ther; 2010 May; 126(2):186-99. PubMed ID: 20206649 [TBL] [Abstract][Full Text] [Related]
10. Control of pulmonary vascular tone during exercise in health and pulmonary hypertension. Merkus D; de Beer VJ; Houweling B; Duncker DJ Pharmacol Ther; 2008 Sep; 119(3):242-63. PubMed ID: 18586325 [TBL] [Abstract][Full Text] [Related]
11. Cellular and molecular pathobiology of pulmonary arterial hypertension. Humbert M; Morrell NW; Archer SL; Stenmark KR; MacLean MR; Lang IM; Christman BW; Weir EK; Eickelberg O; Voelkel NF; Rabinovitch M J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):13S-24S. PubMed ID: 15194174 [TBL] [Abstract][Full Text] [Related]
12. [The cancer paradigm in pulmonary arterial hypertension: towards anti-remodeling therapies targeting metabolic dysfunction?]. Dumas SJ; Humbert M; Cohen-Kaminsky S Biol Aujourdhui; 2016; 210(4):171-189. PubMed ID: 28327277 [TBL] [Abstract][Full Text] [Related]
13. Pulmonary hypertension in dialysis patients. Kosmadakis G; Aguilera D; Carceles O; Da Costa Correia E; Boletis I Ren Fail; 2013; 35(4):514-20. PubMed ID: 23405977 [TBL] [Abstract][Full Text] [Related]
14. The pathogenesis of pulmonary hypertension--an update. Huber LC; Bye H; Brock M; Swiss Med Wkly; 2015; 145():w14202. PubMed ID: 26479975 [TBL] [Abstract][Full Text] [Related]
15. Role of Rho-kinase and its inhibitors in pulmonary hypertension. Duong-Quy S; Bei Y; Liu Z; Dinh-Xuan AT Pharmacol Ther; 2013 Mar; 137(3):352-64. PubMed ID: 23261521 [TBL] [Abstract][Full Text] [Related]